Cara Therapeutics (CARA) Tops Q2 EPS by 18c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. SMCI
6. GOOGL
7. RTX
8. COF
9. TSLA
10. META

Go back to Cara Therapeutics (CARA) Tops Q2 EPS by 18c

Cara Therapeutics Reports Second Quarter 2022 Financial Results

August 8, 2022 4:01 PM EDT

Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia® (difelikefalin)

KOMFORT Phase 2 trial met primary endpoint in notalgia paresthetica, validating potential broad utility of oral difelikefalin across multiple disease categories; FDA meeting expected in 2H 2022

Conference call today at 4:30 p.m. ET

STAMFORD, Conn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical... More